

Summary

This report describes the sexually transmitted disease burden in Garfield County. Primary emphasis is placed on chlamydia and gonorrhea since they are the most frequently reported STDs in Washington State. The 2003 incidence rates by age and sex for gonorrhea and chlamydia are presented.

The report concludes with a presentation of which providers in your county reported STDs.

Contents

County STD Trends	2
Table 1: Washington State Reportable Sexually Transmitted Diseases, 2003	2
<u>Chlamydia</u>	
Chlamydia Incidence Rates, by Age and Gender, 2003	3
<u>Gonorrhea</u>	
Gonorrhea Incidence Rates, by Age and Gender, 2003.....	3
Conclusion	
Table 2: Reported Cases of Gonorrhea and Chlamydia by Provider Type, 2003	4
Appendix A: Data Sources, Analyses, and Limitations.....	5

Garfield County STD Disease Trends

Table 1: Washington State Reportable Sexually Transmitted Diseases, Garfield County, 2003.

Disease	2002 Garfield County Cases	2003 Garfield County Cases	2003 Garfield County Rate ^λ (per 100,000)	2003 Washington State Rate ^λ (per 100,000)
Chlamydia	1	0	-	275
Gonorrhea	0	0	-	45
Early Syphilis	0	0	-	1.9
Congenital Syphilis	0	0	-	0.0 (live births)
Late/Late Latent Syphilis	0	0	-	2.0
Herpes (initial infection)	0	0	-	34
GI/LGV/Chancroid**	0	0	-	0.0
HIV cases**	0	0		
AIDS cases**	0	0		
TOTAL (excluding HIV/AIDS cases)	1	0	*	359

^λ Denominator estimates for the calculation of incidence rates from Washington State Adjusted Population Estimates, OFM, February 2004.

* Rates cannot be calculated for years with fewer than five cases.

** See Appendix A for explanation of disease acronyms.

2003 Compared to 2002:

- Chlamydia had a 100% decrease in reported cases (0 vs. 1).

- Complete information on the HIV/AIDS epidemic in Washington can be found in Washington State HIV/AIDS Surveillance Report, Washington State Department of Health, IDRH, Assessment Unit.

- **Chlamydia**

There were no cases of Chlamydia reported in Garfield County in 2003.

Only women are routinely screened for chlamydia. Because active case-finding is preferentially limited to women, the incidence of chlamydia in men may be under-reported by comparison. Caution should be used in interpreting comparisons of chlamydia rates between genders.

The 2002 STD Treatment Guidelines from CDC recommends that all women diagnosed with chlamydia be re-screened three to four months after treatment. This was suggested because of the high prevalence of chlamydia found in women diagnosed with the disease in the preceding months, presumably as a result of re-infection.

- **Gonorrhea**

There were no cases of gonorrhea reported during 2003.

In Washington State the reported rate in 2003 was 45/100,000, a decrease of 6.6% from 2002 rates and the second annual decrease in rates since 2001. Statewide, the greatest incidence of disease among females, 62% of total female morbidity in 2003, was among 15-24 year olds, while for males the burden of disease is distributed more evenly among those 25 and older. Males had a higher gonorrhea rate (52/100,000) than females (38/100,000). A major factor contributing to the distribution of gonorrhea incidence in different age groups among men or women is the documented outbreak among MSM (men who have sex with men) whose median reported age was 30.

Findings from the Gonococcal Isolate Surveillance Project (GISP) in Seattle have indicated that Washington State is now an area with increased prevalence of quinolone-resistant *Neisseria gonorrhoeae* (QRNG). Based on these findings, the Washington State Department of Health recommends that health care providers in the state should no longer use fluoroquinolones (ciprofloxacin, levofloxacin and ofloxacin) as first line therapy for gonorrhea. The antibiotics of choice are ceftriaxone (Rocephin™) or cefpodoxime (Vantin™) followed with either azithromycin or doxycycline to treat possible coexisting chlamydial infection.

Because most gonorrhea cases are symptomatic and seek medical care, reported cases are considered to be an accurate reflection of true disease incidence in the overall population. Providers in Washington State who reported gonorrhea cases in 2003 indicated that 83% of the men were symptomatic for gonorrhea; 47% of the women were symptomatic.

Conclusion

Table 2: Reported Cases of Chlamydia and Gonorrhea by Provider Type, Garfield County, 2003.

Provider Type	Chlamydia			Gonorrhea		
	No. of Providers	No. of Cases	Percent of Total Cases	No. of Providers	No. of Cases	Percent of Total Cases
Alcohol/Substance Abuse						
Blood Bank/Plasma Center						
Community Health Center						
Emergency Care (excl. hosp.)						
Family Planning						
Health Plan/HMOs						
HIV/AIDS						
Hospitals						
Indian Health						
Jail/Correction/Detention						
Job Corps						
Migrant Health						
Military						
Neighborhood Health						
OB/GYN						
Other						
Private Physicians						
Reproductive Health						
STD Clinics						
Student Health						
TOTAL	0	0		0	0	

The Healthy People 2010 national objectives for chlamydia incidence are:

Females aged 15-24 attending family planning clinics: 3%. There are 0 Region X Infertility Prevention Project (IPP)* Family Planning clinics in Garfield County.

Females aged 15-24 attending STD clinics: 3%.

Males aged 15-24 attending STD clinics: 3%.

There are 0 Region X Infertility Prevention Project (IPP)* STD/Reproductive Health clinics in Garfield County.

The Healthy People 2010 national objective for gonorrhea incidence is 19 cases per 100,000.

*For Region X Chlamydia Project Screening Criteria see page 6.

Appendix A: Data Sources, Analyses and Limitations

Cases: The number of cases identified and submitted by providers to local health jurisdictions and forwarded to the Washington State Department of Health, Office of Infectious Disease and Reproductive Health, STD/TB Services.

Population: Denominator population estimates for incidence rates are from Washington State Adjusted Population Estimates, Office of Financial Management (OFM), February 2004.

Incidence Rates: Incidence rates are calculated as the number of new episodes of a disease (not persons) in a given year divided by the total population (age and sex appropriate) for that year, expressed as a rate per 100,000. Incidence rates allow comparisons between two or more populations by standardizing the denominator and are the most appropriate statistic to use when investigating differences between groups. Rates should not be calculated for incident case totals fewer than five because the rates are unstable.

Data Reporting: Gonorrhea, chlamydia, syphilis, and herpes (initial infection) are reportable diseases to the local health jurisdictions and forwarded to the Department of Health. To be reported and included in surveillance data, disease definition must be met.

Disease Definitions:

- Gonorrhea - isolation of *Neisseria gonorrhea* from a clinical specimen or observation of gram-negative intracellular diplococci in urethral or endocervical smears, culture or non-culture methods.
- Chlamydia- isolation of *Chlamydia trachomatis* from a clinical specimen by culture or non-culture methods that detect chlamydia antigen or genetic material.
- Syphilis - a complex sexual transmitted disease with a highly variable clinical course. See CDC guidelines for surveillance definition.
- Herpes Simplex (initial infection only) - diagnostic criteria for reporting can be made through clinical observation of typical lesions and/or laboratory confirmation.
- Chancroid - an STD characterized by painful genital ulceration and inflammatory inguinal adenopathy.
- Granuloma Inguinale (GI) - a slowly progressive ulcerative disease of the skin and lymphatics of the genital and perianal area.
- Lymphogranuloma Venereum (LGV) - characterized by genital lesions, suppurative regional lymphadenopathy, or hemorrhagic proctitis.
- HIV – Human Immunodeficiency Virus is a retrovirus causing HIV disease and AIDS (Acquired Immunodeficiency Syndrome) in humans. This pathogen is transmitted from person to person through unprotected sexual contact, sharing of injection equipment and transfusion/transplantation with infected blood or tissue.
- AIDS – Acquired Immunodeficiency Syndrome is the advanced stage of HIV-disease in humans and is characterized by severe suppression of immune response. Persons with AIDS are at risk for increased susceptibility to opportunistic infections, degradation of major organ systems and eventual death.

The diagnosing practitioner is responsible for providing the case information which includes patient demographics, source of diagnosis, limited clinical information including site of infection and treatment, and date of diagnosis.

Data Strengths: Sexually transmitted disease data may provide more timely information on behavioral trends in the community than diseases with similar modes of transmission particularly HIV/AIDS. There is a high level of participation in the STD surveillance system by private providers of STD services.

Data Limitations: Clinically diagnosed cases of STDs (without laboratory confirmation) may be missed through this surveillance system. Depending upon diagnosing practices, completeness of reporting may vary by source of health care.

Data Biases: Biases could exist in the data due to under-reporting, inability of certain populations to access medical services, error in laboratory reporting, or differential reporting or screening by disease and source of care. However, it is assumed that the number of cases that would fall into these categories is small and normally distributed, thus not significantly impacting the calculated STD rates.

Assumptions: It is assumed that the cases reported from year to year are independent of each other. One violation of this assumption could be if a person who has an STD one year is more likely to have an STD the following year. Also, repeat episodes of the same STD by the same person are not excluded from the numerator count; it is felt that these numbers are not large enough to significantly impact the calculated incidence rates. Finally, we have assumed that all rates follow a chi-square distribution.

Female Selective Screening Criteria in Family Planning and Expansion Sites:

1. Women 24 and under should be tested at least annually when undergoing a pelvic exam.
2. All women 25 and older who meet one of the following criteria should be screened:
 - a. Cervical findings of mucopurulent cervicitis, friable cervix, ectopy with inflammation or edema,
 - b. PID (Pelvic Inflammatory Disease),
 - c. Exposed to CT in past 60 days,
 - d. Symptomatic sex partner during past 60 days,
 - e. Pregnant,
 - f. Seeking an IUD insertion,
 - g. Prior chlamydial infection within the past 12 months.